Agile Therapeutics is a biotechnology and health care company established in 1997 in the United States. The company is committed to addressing the unmet health needs of women by offering innovative contraceptive options. Their flagship product, Twirla®, is a transdermal system designed to provide women with a hassle-free contraceptive alternative to daily pills or longer-acting methods. Agile Therapeutics leverages its proprietary transdermal patch technology, Skinfusion®, to enable effective drug delivery through the skin. The most recent funding round saw $4.80M in Post-IPO Equity investment on 22 February 2024, indicating ongoing investor confidence in the company’s vision and product pipeline. As Agile Therapeutics continues to make strides in the women's healthcare space, this latest investment is poised to bolster their efforts in transforming the landscape of contraceptive options for women.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $4.80M | - | 22 Feb 2024 | |
| Post-IPO Equity | $7.50M | - | 22 May 2023 | |
| Post-IPO Equity | $4.85M | - | 14 Mar 2022 | |
| Post-IPO Equity | $22.67M | - | 08 Oct 2021 | |
| Post-IPO Debt | $20.00M | 1 |
|
10 Feb 2020 |
No recent news or press coverage available for Agile Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
